New Phase 3 First-in-Class TREMFYA®▼ (guselkumab) Data Show Durability of Joint Efficacy, Including Low Rates of Structural Damage Progression, and a Demonstrated Safety Profile in Adults with Active Psoriatic Arthritis (PsA)
- EMEA Innovative Medicine
- New Phase 3 First-in-Class TREMFYA®▼ (guselkumab) Data Show Durability of Joint Efficacy, Including Low Rates of Structural Damage Progression, and a Demonstrated Safety Profile in Adults with Active Psoriatic Arthritis (PsA)
New Phase 3 First-in-Class TREMFYA®▼ (guselkumab) Data Show Durability of Joint Efficacy, Including Low Rates of Structural Damage Progression, and a Demonstrated Safety Profile in Adults with Active Psoriatic Arthritis (PsA)
- X (Twitter)
Copy link